Primobolan

DHT derivative with 1-methyl modification. Does not aromatize. Weak androgen receptor binding relative to testosterone. Modest anabolic effects. Lower HPTA suppression than most anabolics. The 1-methylation (rather than 17-AA) of the oral form means it is not as hepatotoxic as other oral steroids.

Injectable form uses enanthate ester — methenolone enanthate — providing 7-10 day half-life. Oral form is methenolone acetate — using acetate modification for partial oral bioavailability without full 17-AA modification. Oral bioavailability of methenolone acetate is poor, requiring higher doses than injectable form.

Primobolan has a reputation built largely on association with elite bodybuilders who have claimed to use it, which has given it a mystique somewhat disproportionate to its actual pharmacological potency. In reality it is a mild compound most suited to lean mass maintenance during cutting phases, bridging between cycles, or use in female athletes where the androgenic risk of stronger compounds is not acceptable. Male athletes who use it for primary mass building are generally disappointed because the anabolic effect relative to dose is modest. Its value is in what it does not do: it does not aromatize, it does not cause dramatic HPTA suppression at lower doses, and the injectable form is not hepatotoxic.

Primobolan injectable pairs with Testosterone Enanthate in lean bulk and recomposition protocols where the goal is quality gains with minimal water retention and estrogen management simplicity. It is also used alongside Testosterone and Masteron in cutting phases for female competitors at very low doses where the combined androgenic load remains manageable. In male protocols it sometimes replaces Nandrolone in stacks for users who want to avoid nandrolone-related sexual side effects while still adding a second compound to a testosterone base.

• Muscle wasting in chronic illness
• Malnutrition and underweight conditions
• Pediatric growth promotion (historically)
• Approved in some countries for treatment of anaemia and muscle wasting

• Mild androgenic effects — lower risk than most anabolics
• HPTA suppression — present but milder than testosterone or nandrolone
• HDL suppression — less pronounced than other anabolics
• Oral form — lower hepatotoxicity than 17-AA steroids
• Hair loss in genetically susceptible individuals
• Virilization risk in women — lower than most anabolics

The oral form has poor bioavailability and requires significantly higher doses than the injectable to produce comparable results, which increases the relative cost and the androgenic exposure without proportional benefit. HPTA suppression, while milder than most anabolics, is still present and still requires PCT planning. Hair loss risk is real in genetically susceptible individuals despite the compound's mild reputation. The gap between expected and actual results leads many users to escalate doses, which eliminates the mild risk profile that made the compound appealing in the first place.

Relatively short detection window of 4-5 weeks for injectable. Oral form may clear faster.